MS-IL Revenue and Competitors

Location

N/A

Total Funding

Recruiting

Industry

Estimated Revenue & Valuation

  • MS-IL's estimated annual revenue is currently $28M per year.(i)
  • MS-IL's estimated revenue per employee is $132,000

Employee Data

  • MS-IL has 212 Employees.(i)
  • MS-IL grew their employee count by -1% last year.

MS-IL's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
ControllerReveal Email/Phone
4
Human Resources DirectorReveal Email/Phone
5
Human Resources DirectorReveal Email/Phone
6
Market Director : IndianaReveal Email/Phone
7
Director OperationsReveal Email/Phone
8
Director Sales And Business DevelopmentReveal Email/Phone
9
Director Human ResourcesReveal Email/Phone
10
Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.5M9619%N/AN/A
#2
$28M212-1%N/AN/A
#3
$99.2M661-1%N/AN/A
#4
$6.4M5940%N/AN/A
#5
$4.7M490%N/AN/A
#6
$3.5M363%N/AN/A
#7
$6.2M578%N/AN/A
#8
$1.2M17-29%N/AN/A
#9
$6.5M60-10%N/AN/A
#10
$2.9M3011%N/AN/A
Add Company

What Is MS-IL?

Business Services

keywords:N/A

N/A

Total Funding

212

Number of Employees

$28M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

MS-IL News

2022-04-20 - Lillian Louise Holcomb Obituary (2022) Lake County News Sun

Lillian (Louise) was born in Dorsey, MS on September 24, 1924, ... entombment will follow at Mt. Olivet Cemetery, 1436 Kenosha Rd, Zion, IL.

2022-04-20 - Aneurysmal subarachnoid hemorrhage | CIA

Then, patients were grouped into a poor prognosis group (mRS score ... IL-8, and IL-10 levels were positively correlated with mRS scores.

2022-04-19 - TNF-alpha, IL-6, IL-10 and fatty acids in rheumatoid arthritis patients receiving cDMARD and bDMARD therapy

... while TNF-?, IL-6, and IL-10 gene expression levels were examined by RT-qPCR, and fatty acid levels were examined by GC/MS.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75.8M212N/AN/A
#2
$51.3M212-1%N/A
#3
$35M2127%N/A
#4
$42.2M2134%N/A
#5
$67.9M2135%N/A